45 results about "Annexin A2" patented technology

The invention relates to methods and kits for detecting the likelihood that a subject has cancer, e.g., squamous cell carcinoma, by assaying the expression levels of tumor associated genes. More specifically, the expression levels of nucleic acids or proteins can be assayed in the tumor associated genes, e.g., over-expression of beta-2 microgobulin (B2M), keratin 17 (KRT17), interleukin 8 (IL8), or annexin A2 (ANXA2), and under-expression of cytochrome p450 1B1 (CYP1B1) or laminin gamma-2 (LAMC2) can be indicative of the likelihood a subject has squamous cell carcinoma or a precancerous squamous cell disorder. The expression levels compared to standards can be indicative of the likelihood a subject has squamous cell carcinoma. The expression levels of B2M, CYP1B1, KRT17, IL8, ANXA2, or LAMC2 can also be repeatedly assayed to monitor the progression of a squamous cell neoplasia.

The invention provides a kit for detecting a serum anti-Annexin A2-IgG antibody. The detection kit of the invention adopts a target antigen Annexin A2 corresponding to an anti-Annexin A2-IgG antibodyof a primary nephrotic syndrome-related biomarker, uses human anti-tag peptide IgG as a standard substance for quantitative detection, and utilizes a biotin-labeled detection antibody and an enzyme-labeled streptavidin amplification system, thereby improving the accuracy and sensitivity of serum anti-Annexin A2-IgG antibody detection, and providing a better detection method for the diagnosis and treatment of primary nephrotic syndrome with the anti-Annexin A2-IgG antibody.

The current invention provides Progastrin peptides that specifically bind Annexin A2 overexpressed by epithelial cancers. The invention includes isolated homing Progastrin peptides conjugated to an imaging agent and methods of using the same for the diagnosis of epithelial cancers. Also encompassed are Progastrin peptides conjugated to cytotoxic agents such as Camptothecin, Doxorubicin, Paclitaxel and derivatives thereof, and methods of treating epithelial cancer using the same.

Provided herein is a method for diagnosing / prognosing a metastatic cancer in a subject by measuring and detecting one or more of CS-ANXA2, DCAMKL, Lgr5 or CS-ANAX2 and DCAMKL or CS-ANXA2 and Lgr5 positive circulating tumor stem cells in the subject's blood or plasma. Also provided is a method for distinguishing the presence of early stage primary cancer from advanced stage metastatic cancer in the subject by measuring and detecting AnnexinA2, CS-ANXA2 and DCAMKL−1 or Lgr5 in the blood or plasma. In addition, there is provided a method for distinguishing the presence of benign, pre-cancerous tumorous growths or cancerous tumors in the subject by measuring and detecting AnnexinA2 and circulating tumor stem cells positive for CS-ANXA2 and DCAMKL or CS-ANXA2 and Lgr5 in the blood or plasma.

The invention belongs to the field of gene engineering technology, and provides a small interfering RNA specifically inhibiting annexin A2 acceptor, and application of the siRNA to prepare medicines for treating neovascular diseases. Experiments prove that the siRNA aiming at AXIIR gene expression is capable of inhibiting propagation, migration and blood vessel formation of umbilical vein endothelial cells, and inducing retardance of cell cycle. The siRNA is applicable to prepare stable effective low-toxicity biological targeting preparations or medicines for inhibiting AXIIR expression and treating neovascular diseases.

The present invention relates to an antigen-binding protein, preferably a monoclonal antibody, against annexin A2 (ANXA2), comprising (i) a heavy chain variable domain comprising a VHCDR1 of sequenceGYSITSGYSWH, a VHCDR2 of sequence YIHYSGSTKYNPSLKS and a VHCDR3 of sequence GSNYGFDY; and (ii) a light chain variable domain comprising a VLCDR1 of sequence KSSQSLLYSNDQKNYLA, a VLCDR2 of sequence WASIRES, and a VLCDR3 of sequence QQYYIYPLT. Also provided is an ANXA2 binding protein comprising (i) a heavy chain variable domain comprising a VHCDR1 of sequence VYSITSGYSWH; a VHCDR2 of sequence YIHYSGSTKYNPSLKS, and a VHCDR3 of sequence GTDNAVDY; and (ii) a light chain variable domain comprising a VLCDR1 of sequence KSSQSLLYSSNQKNYLA, a VLCDR2 of sequence WASSRES, and a VLCDR3 of sequence QQYYIYPLT. The antibodies preferably bind to an N-linked glycan on ANXA2, and are internalised upon binding. They may be conjugated with cytotoxins and may be used in the treatment or detection of cancer.

The invention provides a new method and preparation for preventing mycoplasma hyorhinis from infecting cells. Particularly, the invention provides an application of an antagonist for mycoplasma hyorhinis membrane proteins P37 or host cell membrane proteins Annexin A2 in preparation of preparations for preventing mycoplasma hyorhinis from infecting cells or promoting cell migration. According to the invention, the fact that cells are infected with mycoplasma hyorhinis through the interaction between 22 amino acid segments at the amino terminal of a membrane protein P37 on the surface of the mycoplasma hyorhinis and 25 amino acid segments at the amino terminal of a cell membrane protein Annexin A2 is mainly found, so that mycoplasma hyorhinis can be prevented from infecting cells by using anti P37 protein antibodies or antibodies of amino terminal polypeptides of mycoplasma hyorhinis P37, amino terminal polypeptides of Annexin A2, or anti host cell membrane proteins Annexin A2.

The invention relates to application of membranin Annexin A2 of a cell Thp-1 in Angiostrongylus Cantonensis (Ac) protein Galectin-1 induced apoptosis. According to the application of the membranin Annexin A2 of the cell Thp-1 in Ac protein Galectin-1 induced apoptosis, the application provides a theoretical basis for researching applications of a pathogenesis mechanism and control of Ac and treatment of angiostrongyliasis cantonensis and provides a potential acting target, i.e., the Annexin A2 for research and development of treatment drugs; meanwhile, a foundation for research and developmentof angiostrongyliasis cantonensis treatment drugs is laid, and a target is provided for customized treatment of the Ac, so that the application has considerable market prospect and applicability.

The present invention relates to a method for the diagnosis of prostate carcinoma comprising the determination of annexin A3 (ANXA3) and / or autoantibodies against ANXA3 with a specific reagent. The method allows differentiation between benign, premalignant and malignant conditions. Further, the method has a prognostic relevance.

Provided herein is a method for diagnosing / prognosing a metastatic cancer in a subject by measuring and detecting one or more of CS-ANXA2, DCAMKL, Lgr5 or CS-ANAX2 and DCAMKL or CS-ANXA2 and Lgr5 positive circulating tumor stem cells in the subject's blood or plasma. Also provided is a method for distinguishing the presence of early stage primary cancer from advanced stage metastatic cancer in the subject by measuring and detecting AnnexinA2, CS-ANXA2 and DCAMKL-1 or Lgr5 in the blood or plasma. In addition, there is provided a method for distinguishing the presence of benign, pre-cancerous tumorous growths or cancerous tumors in the subject by measuring and detecting AnnexinA2 and circulating tumor stem cells positive for CS-ANXA2 and DCAMKL or CS-ANXA2 and Lgr5 in the blood or plasma.

The invention relates to affinity short peptide for the targeted recognition of Annexin A2 and a preparation method and use of the affinity short peptide. The affinity short peptide can specifically target Annexin A2, and especially the new possibility is provided for the efficient and targeted recognition of tumor tissues and the prediction and improvement of tumor targeted therapy based on the characteristic of high expression of Annexin A2 in most tumors. The polypeptide can be used as a polypeptide molecular probe, or a tumor-directing polypeptide which can be coupled with an anti-tumor drug, is used as a target head to increase the content of the drug or drug-loaded carriers such as a nano-material, liposome and the like in cells over-expressing Annexin A2, and is added with a pharmaceutically acceptable auxiliary material or adjuvant to prepare a novel and more effective targeted anti-cancer drug. The polypeptide provided by the invention can also be prepared into an imaging agent for targeted therapy and imaging of various tumors with high expression of Annexin A2, and can also be prepared into a polypeptide inhibitor for blocking the interaction between Annexin A2 and related proteins. The polypeptide has the specific targeting effect on Annexin A2 and is high in selectivity. The peptide involved in the invention can be prepared through a chemical synthesis method, andis high in purity, small in molecular weight, high in specificity, free of immunogenicity, and safe and reliable.

The invention relates to a blood serum detection method of annexin A2 as well as a detection kit and application thereof, and particularly relates to a method for detecting HCC (Hepatocellular Carcinoma) by independently using a new marker annexin A2 or detecting the HCC by the combination of the annexin A2 and AFP (Alpha Fetal Protein) as well as the detection kit and the application thereof.

The invention generally relates to the field of medicament resistance of chemotherapeutic medicaments, in particular to a method for detecting the expression level of annexin A3 in the supernate of the culture medium of platinum-based chemotherapeutic medicament resisting tumor cells, a method for adjusting the excretion amount of tumor cell annexin A3, a method for evaluating the medicament resistance of patients with tumor to the platinum-based chemotherapeutic medicament, a method for adjusting the platinum releasing of the platinum-based chemotherapeutic medicament resisting tumor cells, a method for combining deoxyribonucleic acid (DNA) and the platinum in the platinum-based chemotherapeutic medicament resisting tumor cells and a method for adjusting the quantity of vesicles in the platinum-based chemotherapeutic medicament resisting tumor cells.

The invention relates to a composition for the treatment of various cancers. The composition is a vaccine containing sequences of EDB, EDA, annexin A1, endosialin, C domain of tenascin C or magic roundabout (MR) or fragments thereof as single or in a combination coupled to one or several heterologous foreign carrier molecules. The vaccine will produce antibodies that are directed against self proteins which are preferentially expressed in and around tumor vessels. The vaccine is preferably administrated together with an adjuvant.

The invention belongs to the technical field of biology, particularly discloses an application of annexin V to the preparation of a medicine for delaying diabetes progression, and specifically comprises an application of the annexin V to the preparation of a medicine for the in preparing a medicament for improving physiological index and metabolism of diabetes, improving insulin signal pathway ofdiabetic model, improving pathological changes of diabetes liver, pancreas and kidney, improving diabetes serum creatinine and urea nitrogen levels, preventing diabetic renal complications or renal function damage and protecting insulinoma cells from apoptosis caused by diabetes inducer streptozotocin.

The invention provides non-invasive assays to reliably identify women who have or are predisposed to developing preeclampsia (PE). The method comprises measuring a level of annexin A2 (ANXA2) in a test sample obtained of a subject; and identifying the subject as having preeclampsia or at an increased risk of developing preeclampsia when the level of ANXA2 in the test sample is decreased in relation to a control sample. Methods to treat subject identified as having PE or at an increased risk of developing preeclampsia are also provided.

The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.

This invention provides compositions and method for inhibiting and treating an HPV infection of LC or tissue containing LC by administering to the LC or tissue an effective amount of an agent that inhibits HPV binding to annexin A2 (ANXA2) present on the surface of the cell, thereby inhibiting HPV infection. It also provides methods to design antiviral and / or anticancer agents for cancers that harbor HPV.

The invention relates to novel use of annexin A3 (ANXA3) and particularly relates to an application of annexin A3 in preparation of a drug for target killing liver cancer stem cells. The invention puts forward the application of using ANXA3 as a liver cancer stem cell related antigen and then inducing to obtain the drug for target killing liver cancer stem cells by using liver cancer stem cell antigen-loaded ANXA3 for the first time. Anti-hepatoma specific immunotherapy based on the drug has a wide clinical application prospect.

The invention provides the design, preparation methods and applications of the variant of annexin V. The variant of annexin V is the protein with amino acid residue sequence in sequence 1 in the SEQUENCE LISTING, characterized in that it is the protein derived from sequence 1 by one or several amino acid residues of the sequence 1 being substituted, missing or being added and its amino acid residues have the same activity with the sequence of the sequence 1. The variant protein of the annexin V prepared form the preparation methods of the variant of the annexin V has high purity, high productivity, high labeling efficiency and stability, without effect to the biological function of the variant of the annexin V, which is applicable to industrial production and allows for further research of the variant of the annexin V.

The present invention relates to a biomarker for early stage ovarian cancer. Specifically, expression of the biomarker Annexin A2 is higher in the plasma of subjects with early stage ovarian cancer. Accordingly, methods of detecting early stage ovarian cancer in a subject, of identifying a subject having early stage ovarian cancer, and of determining if a subject is susceptible to developing ovarian cancer, are provided. Also provided are methods of screening candidate therapeutic agents for use in treating early stage ovarian cancer, and compositions and kits for detecting early stage ovarian cancer in a subject, for identifying a subject having early stage ovarian cancer, and for determining if a subject is susceptible to developing ovarian cancer.

The invention provides an application of thiol and nitrosylation modification of intervention annexin A2 (ANXA2) to preparation of medicines for preventing and treating atherosclerosis related blood vessel diseases, and relates to the field of the cardiovascular system. The thiol and nitrosylation modification level of ANXA2 in blood vessel tissue of animals suffering from atherosclerosis is increased. At cell level, a Cys133 site of mutation ANXA2 can restrain increase of adhesive attachment of THP1 cells and endothelial cells caused by oxLDL, and reduce mRNA level of ICAM1 and VCAM1. At animal level, the Cys133 site of mutation ANXA2 can restrain increase of atherosclerotic plaque caused by high fat diet, reduce mRNA level of ICAM1 and VCAM1 and vascular endothelial dilatation functionsand improve the atherosclerosis related blood vessel diseases. According to the application of the invention, a new preparation method of medicines for preventing and treating the atherosclerosis related blood vessel diseases is developed, and meaningful reference is provided for preventing and treating the atherosclerosis related blood vessel diseases.

Methods for treatment of a multi-drug resistant (MDR) tumor in a subject are disclosed. The methods comprise administering to the subject in need of treatment a therapeutically effective amount of ananti-mycoplasma agent and / or an agent blocking the interaction between membrane protein P37 of mycoplasma and Annexin A2 of host cells of the subject, prior to, at the same time with, or after chemotherapy. Relevant pharmaceutical compositions, kits, uses are also disclosed.